Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) Price Target at $3.33

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $3.3333.

CGTX has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 4th. Wall Street Zen raised Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. B. Riley restated a “buy” rating and set a $3.00 price objective (up previously from $2.00) on shares of Cognition Therapeutics in a report on Friday, November 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday.

Cognition Therapeutics Price Performance

CGTX stock opened at $1.54 on Wednesday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The firm has a market cap of $135.94 million, a PE ratio of -3.21 and a beta of 1.23. The firm has a 50 day simple moving average of $1.64 and a 200 day simple moving average of $1.33.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. As a group, sell-side analysts expect that Cognition Therapeutics will post -0.8 earnings per share for the current year.

Institutional Trading of Cognition Therapeutics

Several large investors have recently added to or reduced their stakes in CGTX. Jones Financial Companies Lllp purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at $25,000. Northeast Financial Consultants Inc raised its position in Cognition Therapeutics by 158.6% during the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock valued at $27,000 after buying an additional 38,851 shares during the period. Gamco Investors INC. ET AL purchased a new stake in Cognition Therapeutics in the 3rd quarter worth about $27,000. Private Management Group Inc. acquired a new stake in Cognition Therapeutics during the 3rd quarter worth about $32,000. Finally, CWA Asset Management Group LLC acquired a new stake in Cognition Therapeutics during the 3rd quarter worth about $34,000. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.